UNSPSC 51373450: Codeine/phenylephrine/potassium guaiacolsulfonate/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373450 Codeine/phenylephrine/potassium guaiacolsulfonate/promethazine is a Commodity code that does not reflect the actual pharmaceutical and medical products state and local governments are procuring under this designation. Recent opportunities tagged to this code center on parenteral products (including IV solutions, total parenteral nutrition, and peripheral parenteral nutrition), naloxone, and drug deactivation systems — a scope substantially broader than the specific drug combination the code name implies. State and local issuing bodies soliciting under this code include correctional departments and county health agencies. The Washington State Department of Corrections represents the largest recent buyer, procuring parenteral products and services across multiple facilities with expedited delivery requirements (24-hour turnaround for nutrition bags, 8-hour turnaround for other products) and strict quality-control standards around preparation and patient monitoring.

Activity under this code appears concentrated in the Pacific Northwest and Southeast. Washington state has posted the most recent and substantive opportunity—RFQ RFQQK13020, due October 7, 2026, seeking parenteral products and services for eight correctional facilities across three regions, with DOC planning to select up to three contractors per region and offering set-asides for small businesses (25%), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%). Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries, though the response date listed (July 26, 2023) appears to be a data error. Both opportunities impose strict insurance and compliance requirements, including E-Verify and drug-free workplace certification, and award contracts on a fixed-fee basis with multi-year terms and renewal options.